Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4175.20 +1.6% SILVER 56.91 +1.9% COPPER 6.54 −1.8% OIL 96.60 +1.6% PALLADIUM 1133.75 +3.4% CLCH 1.06 −3.6% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9% EVI 0.520 +4.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.240 −2.0% BAU 0.180 −5.3% TECT 1.70 +2.4% TOM 0.140 +3.7% FVL 0.915 +1.7% HART 0.195 +0.0% VLD 0.415 +0.0% GOLD 4175.20 +1.6% SILVER 56.91 +1.9% COPPER 6.54 −1.8% OIL 96.60 +1.6% PALLADIUM 1133.75 +3.4% CLCH 1.06 −3.6% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9% EVI 0.520 +4.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.240 −2.0% BAU 0.180 −5.3% TECT 1.70 +2.4% TOM 0.140 +3.7% FVL 0.915 +1.7% HART 0.195 +0.0% VLD 0.415 +0.0%

Healthcare

Page 23
  1. May 07, 2026 · 06:30 · GUD · Material +

    Knight Therapeutics Q1 Earnings Beat Drives Guidance Hike Amidst LATAM Expansion

    Knight Therapeutics Reports First Quarter 2026 Results

    01
  2. May 06, 2026 · 19:22 · CRRX · Routine +

    CareRx Maintains Growth Trajectory Amidst Ontario Funding Stability, Yet Regulatory Nuances Persist

    CareRx Reports Results for The First Quarter of 2026

    02
  3. May 06, 2026 · 17:00 · SEGN · Routine −

    Filing Default Lingers as Seegnal Pushes Audit Deadline

    Seegnal Inc. Announces Update to Delay in Filing 2025 Annual Financial Statements and Related Management Discussion and Analysis

    03
  4. May 06, 2026 · 16:01 · INNO · Routine +

    Innocan Pharma Shares Tumble 73% as Revenue Slips; Media Feature Fails to Halt Downtrend

    Innocan Pharma LPT-CBD is featured in Pain Medicine News

    04
  5. May 06, 2026 · 08:00 · 4151 · Routine +

    Kyowa Kirin Expands CRYSVITA Access, But Oncology Pipeline Risks Loom

    CRYSVITA(TM) Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program

    05
  6. May 06, 2026 · 07:30 · BCT · Routine +

    Pipeline Progression Confirmed as Phase 3 Data Looms

    BriaCell Receives FDA Clearance to Initiate Bria-BRES+(TM) Clinical Study in Breast Cancer

    06
  7. May 06, 2026 · 07:15 · BLCO · Routine +

    Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

    Bausch + Lomb Announces Second R&D "Teach-in" Webinar

    07
  8. May 06, 2026 · 07:00 · EPRX · Routine +

    Eupraxia Confirms Fibrosis Reversal in EoE, But Phase 2b Readout Remains Key Catalyst

    Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

    08
  9. May 06, 2026 · 06:00 · LOBE · Routine +

    Lobe Sciences Secures Funding But Burn Rate Accelerates Amidst Clinical Progress

    Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress

    09
  10. May 05, 2026 · 19:11 · TLT · Routine −

    Theralase Secures Runway Amidst Dilution Concerns and Revenue Decline

    Theralase(R) Announces $4 Million Brokered LIFE Offering

    10
  11. May 05, 2026 · 18:00 · ONCO · Neutral

    Onco-Innovations GSK Deal Fails to Halt Penny Stock Slide Amidst Dilution Concerns

    Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation

    11
  12. May 05, 2026 · 18:00 · ZYUS · Routine +

    Patent Grant Offers IP Shield Amidst Liquidity Crunch and Regulatory Filing Delays

    ZYUS Life Sciences Expands U.S. Patent Portfolio with Second Pain Management Patent

    12
  13. May 05, 2026 · 13:30 · KDA · Neutral

    Governance Cleanup Amidst Valuation Trough

    KDA GROUP ANNOUNCES RESULTS OF SHAREHOLDERS' ANNUAL GENERAL MEETING AND THE SETTLEMENT OF JUDICIAL CLAIMS

    13
  14. May 05, 2026 · 10:40 · AIAI · Routine +

    NetraMark TSX Listing Confirms Exchange Status But Price Divergence Signals Skepticism Over Revenue Conversion

    NetraMark Holdings Inc. (AIAI) Opens the Market

    14
← Newer Older →